CD20-targeted CAR-T cell therapy
Drug timelines are a Plus or Pro feature.
2 regulatory and trial events tracked for CD20-targeted CAR-T cell therapy, covering 2016-09-07 to 2025-04-16. Get the full timeline:
Most recent: Clinical Trial Update: A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas [Phase 1, Phase 2]